Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed the MEX-DM-302 Study (ATLAS Study)

NCT06549400 is registered in ClinicalTrials.gov with Lupin Ltd. as lead sponsor.

NCT NCT06549400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06549400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed the MEX-DM-302 Study (ATLAS Study)
Lead sponsor
Lupin Ltd.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
September 12, 2025
Completion date
July 6, 2028
Enrollment
176 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

myotonic dystrophy